Skip to main content

Table 3 Comparisons of VAS between curcumin supplement and placebo

From: Effect of curcumin supplement or placebo in delayed onset muscle soreness: a systematic review and meta-analysis

Author Curcumin Placebo
N Mean SD N Mean SD
(a) VAS preexercise
Nicol LM 17 0 0 17 0 0
Tanabe Y 14 0.68 0.91 14 0.34 0.57
McFarlin BK 14 0.16 0.53 14 0.21 0.63
Naknhostin-Roohi B 10 5.93 0.19 10 5.93 0.37
Basham SA 20 3.089 0.206 20 3.795 0.206
Amalraj A (VAS 0–4) 15 2.91 0.36 15 2.65 0.459
Jäger R (200 mg) 21 0 0 21 0 0
Tanabe Y (pre) 8 0.833 0.625 8 1.04 0.94
Tanabe Y (post) 8 1.04 1.25 8
Tanabe Y scan (0–10) pre 10 0.676 0.795 10 0.636 0.477
Tanabe Y scan (0–10) post 10 0.954 1.113 10 1.193 1.113
Mallard AR (0–10) 13 0.375 0.625 14 0.375 0.5
Hillman AR 11 0.149 0.223 11 1.334 2.074
UMD (95% CI)      − 0.12 (− 0.46, 0.22)   
(b) VAS post-exercise
Nicol LM 17 2 1.5 17 1.75 1.75
Tanabe Y 14 1.36 1.48 14 1.42 1.59
Jäger R (50 mg) 2.97 1.73 21
Jäger R (200 mg) 21 2.14 0.99 21 2.97 1.81
Tanabe Y (pre) 8 1.04 0.833 8 1.56 1.87
Tanabe Y (post) 8 1.46 1.88 8
Tanabe Y scan (0–10) pre 10 0.795 0.795 10 1.113 2.385
Tanabe Y scan (0–10) post 10 1.431 1.67 10 1.749 1.749
Mallard AR (0–10) 13 3 2.5 14 2.5 2.25
Hillman AR 11 0.963 1.334 11 2.963 2.963
UMD (95%CI)      − 0.38 (− 0.83, 0.08)   
(c) VAS at 24 h
Nicol LM 17 2.87 1.33 17 3 2
Tanabe Y 14 4.32 2.5 14 4.77 1.82
McFarlin BK 14 3.53 0.32 14 4.84 0.63
Naknhostin-Roohi B 10 6.48 0.09 10 6.85 0.19
Jäger R (50 mg) 5.36 1.81 21
Jäger R (200 mg) 21 3.63 0.99 21 5.53 1.65
Tanabe Y (pre) 8 4.375 1.458 8 4.69 2.29
Tanabe Y (post) 8 3.44 1.46 8
Tanabe Y scan (0–10) pre 10 3.975 1.272 10 3.657 1.272
Tanabe Y scan (0–10) post 10 4.216 1.91 10 3.897 1.67
Mallard AR (0–10) 13 1.625 1.813 14 2.188 1.875
Hillman AR 11 2.667 1.778 11 4.667 3.482
UMD (95%CI)      − 0.67 (− 1.19, − 0.16)   
(d) VAS at 48 h
Drobnic F 9 2.33 0.79 10 3.06 7.9
Nicol LM 17 2.2 1.33 17 3.2 2.2
Tanabe Y 14 5.45 2.05 14 5.97 2.27
McFarlin BK 14 5.26 0.42 14 6.95 0.63
Naknhostin-Roohi B 10 6.67 0.19 10 8.33 0.19
Jäger R (50 mg) 4.289 1.98 21
Jäger R (200 mg) 21 3.88 0.99 21 4.289 2.23
Tanabe Y (pre) 8 7.083 1.667 8 5.94 2.6
Tanabe Y (post) 8 4.89 1.67 8
Tanabe Y scan (0–10) pre 10 6.519 0.954 10 5.724 1.272
Tanabe Y scan (0–10) post 10 5.408 1.83 10 6.208 1.67
Cardaci TD 11 4.66 1.58 12 6.12 1.58
Mallard AR (0–10) 13 0.813 0.876 14 1.25 0.875
Hillman AR 11 2.667 1.852 11 5.408 3.26
UMD (95% CI)      − 0.86 (− 1.38, − 0.34)   
(e) VAS at 72 h
Tanabe Y 14 4.66 2.5 14 5 2.5
McFarlin BK 14 1.89 0.42 14 3.89 0.63
Naknhostin-Roohi B 10 6.85 0.09 10 7.96 0.19
Basham SA 20 2.5 0.206 20 2.912 0.206
Jäger R (50 mg) 1.65 1.73 21
Jäger R (200 mg) 21 1.73 0.91 21 1.4 1.65
Tanabe Y (pre) 8 6.04 1.35 8 6.15 1.46
Tanabe Y (post) 8 4.06 1.25 8
Tanabe Y scan (0–10) pre 10 5.565 1.272 10 5.247 1.749
Tanabe Y scan (0–10) post 10 4.77 1.83 10 6.758 0.875
Mallard AR (0–10) 13 0.188 0.438 14 0.5 0.375
Hillman AR 11 1.112 1.186 11 4.445 3.112
UMD (95%CI)      − 0.81 (− 1.27, − 0.36)   
(f) VAS at 96 h
Tanabe Y 14 2.84 2.95 14 3.3 2.61
McFarlin BK 14 0.53 0.32 14 1.79 0.63
Amalraj A (VAS 0–4) 15 1.122 0.56 15 2.35 0.51
Tanabe Y (pre) 8 3.54 1.67 8 5.31 2.71
Tanabe Y (post) 8 3.33 1.88 8
Tanabe Y scan (0–10) pre 10 3.18 1.749 10 3.419 1.749
Tanabe Y scan (0–10) post 10 3.737 1.988 10 6.042 1.272
UMD (95%CI)      − 1.24 (− 1.50, − 0.99)